Phase 3 Randomized Trial Data Shows SBRT has Similar Acute Safety Profile to Conventional Radiation Therapy in Patients with Localized Prostate Cancer - Seite 2
The prostate gland can move unpredictably throughout the course of treatment because of normal patient bodily functions. This makes it vitally important to be able to track, detect and correct for all types of motion. The CyberKnife System, designed to deliver SBRT, is the only radiotherapy device that can track and automatically correct for prostate motion and maintain sub-millimeter accuracy throughout treatment delivery, thereby enhancing clinicians' ability to treat effectively while preserving healthy tissue.
"The results of this randomized controlled trial add to the large body of evidence supporting the use of SBRT as a treatment option for low- and intermediate-risk prostate cancer. The data are important because they have the potential to impact clinicians' approach to the treatment of this disease," said Fabienne Hirigoyenberry-Lanson, Ph.D., Vice President Global Medical and Scientific Affairs at Accuray. "Our CyberKnife System provides a valuable option for delivering prostate SBRT. Data reinforce that treatment with the system results in minimal side effects and impact on quality of life during and after treatment."
About the PACE-B Trial
PACE-B, an international phase 3 randomized controlled trial comparing stereotactic body radiotherapy to conventionally fractionated or moderately
hypofractionated external beam radiotherapy (CFMHRT) for localized prostate cancer, represents one arm of a two-part trial. Further data on this arm, as well as the second arm comparing
hypofractionated SBRT to prostatectomy, will be shared when available. Out of the 874 patients enrolled by 38 institutions, 845 patients were analyzed; 431 receiving SBRT and 414 CFMHRT. Men who
were unsuitable for surgery or preferred treatment with external beam radiation therapy were eligible to participate. The trial evaluated the treatment regimens across multiple effectiveness and
safety metrics; toxicity measures were presented at ASCO GU.
Lesen Sie auch
About Accuray
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative treatment solutions that set the standard of
care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more
information, please visit www.accuray.com or follow us on Facebook, LinkedIn, Twitter and YouTube.